title: Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.
abstract: BACKGROUND
  Prostate cancer is a common malignancy in men, and inevitably some patients experience biochemical recurrence after radical prostatectomy. To date, there are no reliable predictors for prostate cancer recurrence, and novel predictors are urgently needed. PCDH10 (protocadherin-10) is a novel tumor suppressor gene, which is down-regulated by promoter methylation in prostate cancer. The aim of this study was to evaluate the feasibility of using PCDH10 methylation to predict the biochemical recurrence (BCR) of prostate cancer after radical prostatectomy.
  
  
  METHODS
  Fresh tissue samples were obtained from 151 patients with primary prostate cancer, and from 34 patients with benign prostatic hyperplasia (BPH) as control. The methylation status of PCDH10 in prostate cancer tissues and controls were examined using methylation-specific PCR (MSP), and then associated with clinicopathological features and BCR-free survival of patients with prostate cancer.
  
  
  RESULTS
  We found that PCDH10 methylation was detected in 79 (52.3%) patients with prostate cancer, but no methylation was found in controls (P<0.0001). Moreover, PCDH10 methylation was significantly associated with higher preoperative prostate-specific antigen (PSA) level (P <0.0001), higher Gleason Score (P<0.0001), advanced clinical stage (P=0.0002), lymph node metastasis (P=0.0389), angiolymphatic invasion (P=0.0303), and biochemical recurrence (P=0.0068). Moreover, PCDH10 methylation was associated with poor BCR-free survival (P<0.0001), and may be used as an independent predictor of BCR-free survival (P=0.0046).
  
  
  CONCLUSIONS
  Our results indicate that PCDH10 methylation in prostate cancer tissue is an independent prognostic biomarker of worse BCR-free survival of patients with prostate cancer after radical prostatectomy.
authors.affiliation: Department of Urology, Affiliated Hospital, Hebei University of Engineering, Handan, Chile.
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Spine Surgery, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (mainland).
authors.forename: Pei-Gen
authors.initials: PG
authors.lastname: Xie
authors.affiliation: Department of Urology, Xuzhou Tumor Hospital (Affiliated Xuzhou Hospital of Jiangsu University), Xuzhou, China (mainland).
authors.forename: Ying-Li
authors.initials: YL
authors.lastname: Lin
authors.affiliation: Department of Urology, Third Hospital, Hebei Medical University, Shijiazhuang, China (mainland).
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Ma
authors.affiliation: Department of Urology, Third Hospital, Hebei Medical University, Shijiazhuang, China (mainland).
authors.forename: Wen-Ping
authors.initials: WP
authors.lastname: Li
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D015820:Cadherins / Q000235:genetics / Q000378:metabolism; D019175:DNA Methylation / Q000235:genetics*; D017931:DNA Primers / Q000235:genetics; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D016133:Polymerase Chain Reaction; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000601:surgery*; D000091363:Protocadherins
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; D017931:DNA Primers; C438603:PCDH10 protein, human; D000091363:Protocadherins
references.citation: Dis Markers. 2011;30(4):151-61
references.pmid: 21694441
references.citation: Urology. 2013 Feb;81(2):354-7
references.pmid: 23374801
references.citation: Genes Chromosomes Cancer. 2013 Nov;52(11):1030-41
references.pmid: 23929756
references.citation: Cancer Treat Rev. 2014 Feb;40(1):3-11
references.pmid: 23896177
references.citation: Urol Int. 2013;90(2):219-24
references.pmid: 23171734
references.citation: J Int Med Res. 2012;40(6):2117-23
references.pmid: 23321168
references.citation: Cancer Lett. 2014 Jan 28;342(2):248-56
references.pmid: 22391123
references.citation: Cancer Causes Control. 2013 Sep;24(9):1615-41
references.pmid: 23797237
references.citation: Curr Genomics. 2011 Nov;12(7):486-505
references.pmid: 22547956
references.citation: Med Sci Monit. 2014 May 19;20:818-24
references.pmid: 24835144
references.citation: Eur Urol. 2013 Dec;64(6):905-15
references.pmid: 23721958
references.citation: Med Sci Monit. 2011 Feb;17(2):CR104-9
references.pmid: 21278686
references.citation: World J Urol. 2013 Apr;31(2):253-9
references.pmid: 22763628
references.citation: Am J Case Rep. 2014 Jun 20;15:266-70
references.pmid: 24967002
references.citation: Clin Cancer Res. 2012 May 15;18(10):2882-95
references.pmid: 22589488
references.citation: Cell Biol Int. 2011 Jul;35(7):671-6
references.pmid: 21314642
references.citation: J Urol. 2007 May;177(5):1753-8
references.pmid: 17437806
references.citation: Urol Int. 2008;81(1):29-35
references.pmid: 18645268
references.citation: Res Rep Urol. 2013 Oct 21;5:139-45
references.pmid: 24400245
references.citation: Methods Mol Biol. 2012;863:47-66
references.pmid: 22359287
references.citation: J Int Med Res. 2013 Feb;41(1):38-47
references.pmid: 23569128
references.citation: Onco Targets Ther. 2014 Jan 24;7:137-46
references.pmid: 24493929
references.citation: Am J Pathol. 2013 Dec;183(6):1960-1970
references.pmid: 24113458
references.citation: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references.pmid: 24399786
references.citation: Arch Esp Urol. 2011 Oct;64(8):681-94
references.pmid: 22052751
references.citation: Cancer Biomark. 2012-2013;12(1):11-9
references.pmid: 23321465
references.citation: Nat Rev Urol. 2014 Apr;11(4):197-212
references.pmid: 24595118
references.citation: Crit Rev Clin Lab Sci. 2014 Aug;51(4):173-99
references.pmid: 24878394
references.citation: J Clin Oncol. 2013 Sep 10;31(26):3250-8
references.pmid: 23918943
references.citation: Br J Cancer. 2013 Aug 6;109(3):807-13
references.pmid: 23839493